Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Patient Population Type: Advanced Muscle Invasive Bladder Cancer
Prior Therapy: One prior therapy for advanced disease
Disease: Measurable disease
ECOG Performance: 0,1
Indication: Histologically Proven Carcinoma of the bladder
For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception
Allergies: No known allergy to one of the study drugs
Patient Status:
No CNS metastases
No peripheral neuropathy > grade1
No other serious concomitant illness
Fully recovered from any prior therapy
Informed Consent: Patient and doctor have signed informed consent
Lower Age Limit: Lower age limit >18
Upper Age Limit: Upper Age Limit <70
ANC: ANC >1500/mm3 or WBC > 3000/mm3
Platelets: Platelets >100,000/mm3
Creatinine: Creatinine <1.8mg/dL
Bilirubin: Bilirubin <=2.0 x ULN
SGPT: SGPT (ALT) <=1.5 x ULN (<4xULN if liver metastases present)
RBC: Hemoglobin > 9.0g/dL
Cardiovascular: No active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months
Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma)
No prior exposure to Oxaliplatin
No cytotoxics or radiation 4 weeks prior to enrolling on protocol
PT/PTT normal